Asceneuron

0 followers


Asceneuron develops effective therapeutics for orphan tauopathies and Alzheimer’s disease.

Employees

11-50

Links


Org chart

Barbara Angehrn Pavik
Chief Executive Officer
Collapse
Sandra Millet
Head Of Operations
Eric Yuen
Scientific Advisory Board Member
Andrin Cerletti
Head Of Business Development
Ruhi Ahmed
SVP & Head of Regulatory Affairs
Bruno Permanne
Senior Director & Head of Preclinical Development
Colin Kahrs
Head of Intellectual Property

Board & advisors

Hakan Goker
Director
Eric Yuen
Director
Raymond G. Hill
Scientific Advisor
Christian Haass
Scientific Advisor
Adam Boxer
Scientific Advisor
Günter U. Höglinger
Scientific Advisor